Principal Investigator: Prof. Liam Heaney
Name of the Study: SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients with Severe Eosinophilic Asthma Treated with Benralizumab
Why is this Study important? This study aims to assess the potential for Fasenra®-treated severe eosinophilic asthma patients to safely and effectively reduce their Symbicort® maintenance asthma treatment burden while maintaining asthma symptom control.
What is the Research question/aim? The rationale for this study is to explore a new precision-based approach to treat severe eosinophilic phenotype asthma patients based on benralizumab (Fasenra®) maintenance treatment plus budesonide/formoterol (Symbicort® 200/6 μg) anti-inflammatory reliever as needed.
Who can take part in the Study? Patients with severe eosinophilic asthma treated with Benralizumab
Contact Information:
Roisin Stone
Belfast Health and Social Care Trust
51 Lisburn Road
Tel: 02895 041135
Location:
NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB
Tel:+44 (0)28 9504 0342
Email:NICRF@qub.ac.uk
